A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler (TIOSPIR)

Trial Profile

A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler (TIOSPIR)

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs Tiotropium bromide (Primary) ; Tiotropium bromide
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms TIOSPIR
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 04 Aug 2016 Results of sub-analysis (n=2356) published in the Respirology (2016).
    • 18 May 2016 Results assessing association between body mass index (BMI), mortality and exacerbation risk presented at the 112th International Conference of the American Thoracic Society
    • 28 Mar 2016 Results of pooled analysis of this and other 5 trials (see profiles: 15373, 270480, 270481, 270485 and 60495) published in the Advances in Therapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top